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Identity 
HGNC (Hugo): EPHA3 
Location: 3p11.1 
Other names: EC 2.7.10.1, ETK, ETK1, EphA3, 
HEK, HEK4, TYRO4 
Local order 
(tel) C3orf38 (ENSG00000179021) ->, 949,562bp, 
EPHA3 (374,609bp) ->, 720,071bp, <- 
AC139337.5 (ENSG00000189002) (cen) 
Note 
EPHA3 is flanked by two gene deserts. 
Figure 1: Chromosomal location of EPHA3 (based on Ensembl Homo sapiens version 53.36o (NCBI36)). 
Figure 2: Genomic neighbourhood of EPHA3 (based on Ensembl Homo sapiens version 53.36o (NCBI36)). 
Figure 3: Genomic organisation of EPHA3. 
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EPHA3 spans the human tile path clones CTD-
2532M17, RP11-784B9 and RP11-547K2. 
Description 
EPHA3 consists of 17 exons and 16 introns and 
spans 375kb of genomic DNA. It is the second 
largest of the EPH genes after EPHA6. 
Transcription 
Two alternatively spliced transcript variants have 
been described (NM_005233.5, a 5,807 nucleotide 
mRNA and NM_182644.2, a 2,684 nucleotide 
mRNA). The shorter transcript results in truncation 
within the extracellular domain of EphA3 and is 
predicted to produce a soluble protein. The 5' end of 
EPHA3 is associated with a CpG island, a feature 
common to all EPH genes. The EPHA3 promoter 
also lacks a TATA box and transcription initiates 





The Eph receptors constitute the largest of the 20 
subfamilies of human receptor tyrosine kinases. 
The founding member of this group was isolated 
originally from an erythropoietin producing 
hepatoma cell line. 
Description 
The EPHA3 gene encodes a 983 amino acid protein 
with a calculated molecular weight of 110.1kDa 
and an isoelectric point of 6.7302. Amino acids 1-
20 constitute a signal peptide. The predicted 
molecular mass of the translated protein minus the 
signal peptide is 92.8kDa. The 521 amino acid 
extracellular domain contains five potential sites for 
N-glycosylation such that EphA3 is typically 
detected as a 135kDa glycoprotein. This mature 
isoform of EphA3 is a single-pass transmembrane 
receptor tyrosine kinase. Eph receptors have a 
conserved domain structure: At the N-terminus is a 
≈ 174 amino acid ligand binding domain, followed 
by a ≈114 amino acid cysteine-rich domain 
subdivided into complement control protein (CCP, 
or sushi) and EGF-like domains and two membrane 
proximal fibronectin type III repeats. Amino acids 
21-376 of the extracellular domain are rich in 
cysteine residues. The intracellular domain contains 
the tyrosine kinase domain and a sterile alpha 
motif. EphA3 lacks a PDZ domain interacting motif 
present in EphA7, EphB2, EphB3, EphB5 and 
EphB6. Activation of the EphA3 receptor tyrosine 
kinase domain is associated with two tyrosine 
residues in the juxtamembrane region (Y596, 
Y602) that are sites of autophosphorylation and 
interact with the kinase domain to modulate its 
activity. 
EphA3 belongs to an evolutionarily ancient 
subfamily of receptor tyrosine kinases with 
members being present in sponges, worms and fruit 
flies. The expansion in the number of Eph receptor-
encoding genes along with genes encoding their 
ligands, the ephrins (Eph receptor interacting 
proteins), is proposed to have contributed to the 
increase in complexity of the bilaterian body plan. 
Genes encoding EphA3 are found in the genomes 
of representative members of at least five of the 
seven classes of vertebrates including bony fish 
(zebrafish, pufferfish, medaka), amphibians 
(African clawed frog), reptiles (green anole lizard), 
birds (chicken) and mammals (platypus, possum, 
human). 
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Fourteen Eph receptors have been identified in 
vertebrates. These are subdivided into either EphA 
(EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, 
EphA7, EphA8, EphA10) or EphB (EphB1, EphB2, 
EphB3, EphB4, EphB6) subclasses which differ 
primarily in the structure of their ligand binding 
domains. EphA receptors also exhibit greater 
affinity for binding GPI-linked ephrin-A ligands 
while EphB receptors bind transmembrane ephrin-
B ligands. While interactions are somewhat 
promiscuous, and some cross-class binding occurs, 
each Eph receptor displays distinct affinity for the 
different ephrin ligands. The high affinity ligands 
for EphA3 are ephrin-A2 and ephrin-A5. EphA3 
also binds ephrin-A3 and ephrin-A4 with lower 
affinity. 
Eph-ephrin binding involves contact between cells. 
Upon binding, receptor-ligand dimers form 
heterotetramers, which further assemble into higher 
order signalling clusters. Several moieties in the 
EphA3 receptor extracellular region mediate ephrin 
binding. A high-affinity binding site in the N-
terminal ephrin binding domain mediates 
intercellular Eph-ephrin interaction. Structural 
studies show the interaction between ephrin-A5 and 
EphA3 is slightly tilted relative to its binding to 
EphA2, resulting in a greater interaction surface . 
Mutation studies show two additional lower-affinity 
ephrin-binding sites, one in the ephrin-binding 
domain and the other in the cysteine-rich region, are 
involved in clustering of the EphA3-ephrin-A5 
complex. Receptor clustering is further facilitated 
by receptor-receptor interactions within the ligand-
binding domain and the adjacent cysteine-rich 
domain , which can also lead to heterologous 
clustering with different Eph subtypes . 
Following ephrin-A5-mediated EphA3 receptor 
clustering, intracellular signalling by EphA3 
receptors is initiated by autophosphorylation of 
three defined tyrosine residues, two in the highly 
conserved juxtamembrane region and the third in 
the activation loop of the kinase domain (Y779). 
Rapid reorganisation of the actin and myosin 
cytoskeleton follows, leading to retraction of 
cellular protrusions, membrane blebbing and cell 
detachment, following association of the adaptor 
protein CrkII with tyrosine phosphorylated EphA3 
and activation of RhoA signalling. 
Such Eph-ephrin interaction triggers bidirectional 
signalling, that is signalling events within both Eph- 
and ephrin-bearing cells, an unusual phenomenon 
for receptor tyrosine kinases, most of which interact 
with soluble ligands. Subsequently, depending on 
the cellular context (including the identity of the 
interacting Eph-ephrin receptor-ligand pairs, their 
relative levels on interacting cells, the presence of 
additional Ephs and ephrins and their alternative 
isoforms, and the net effect of interaction with 
additional signalling pathways) this either results in 
repulsion or promotes adhesion of the interacting 
cells. 
Cellular repulsion and the termination of Eph-
ephrin signalling require disruption of the receptor-
ligand complex. This is brought about either by 
enzymatic cleavage of the tethered ephrin ligand or 
by trans endocytosis of Eph-ephrin complexes. 
EphA3-ephrin-A receptor-ligand complexes are 
disrupted following receptor-ligand binding when 
ADAM10 (a disintegrin and metalloprotease 10), 
cleaves ephrin cleaves ephrin, to allow cells to 
separate. ADAM10 association via its substrate 
recognition motif, and cleavage of ephrin, are 
dependent on ephrin/EphA3 binding and on EphA3 
kinase activation. The post-cleavage ephrin-A5-
EphA3 complex is then endocytosed by the EphA3-
expressing cell. 
While cellular repulsion is often the outcome of 
Eph-ephrin interaction, in some circumstances 
adhesion may persist, particularly when there is low 
Eph kinase activity. For example, ADAM10 has 
been observed not to cleave ephrin-A5 following 
EphA3-ephrin-A5 interaction involving LK63 cells 
in which high intracellular protein tyrosine 
phosphatase activity also appears to counter ephrin-
A5 stimulated phosphorylation of EphA3, holding 
the receptor in an inactive, unphosphorylated state. 
The phosphatase PTP1B is known to directly 
regulate EphA3 activity, and its overexpression 
inhibits receptor endocytosis at cell-cell contacts . 
Another mechanism that may favour stable cell-cell 
adhesion involves truncated Eph receptor isoforms 
acting in a dominant negative manner. While 
activation of full length EphA7 by ephrin-A5 
results in cellular repulsion, ephrin-A5-induced 
phosphorylation of EphA7 is inhibited by 
expression of two EphA7 splice variants with 
truncated kinase domains, which act in a dominant 
negative manner, and adhesion results. A splice 
variant of EPHA3 also has been reported, truncated 
before the transmembrane domain, and predicted to 
give rise to a soluble isoform of EphA3, the 
function of which has not been established. In 
addition, a number of EphA3 mutations have been 
described in various cancers (see below), at least 
some of which inhibit activity and cell-surface 
localisation of the receptor , and can act as 
dominant negative mutants to inhibit activity of Wt 
receptor . 
While important details of EphA3 signalling have 
been determined, more complete understanding of 
EphA3 activity will require knowledge of the full 
complement of EphA3 interacting proteins. 
Substrates that are targets for the tyrosine kinase 
activity of EphA3 have yet to be defined and 
potential mediators or modulators of EphA3 
signalling output such as Src family kinases, 
additional phosphotyrosine binding adaptors, SAM 
domain interacting factors, interaction with other 
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receptor kinases and crosstalk with other signalling 
pathways, and the regulatory role of phosphatases 
all remain to be explored. Based on the range of 
interacting proteins identified for other Eph 
receptors (some common to more than one Eph, 
others apparently unique to individual Ephs) 
additional effectors of EphA3 signalling output are 
likely. 
Expression 
EphA3 was first identified as an antigen expressed 
at high levels (10,000-20,000 copies per cell) on the 
surface of the LK63 pre-B cell acute lymphoblastic 
leukaemia cell line. It also was found to be 
expressed by JM, HSB-2 and MOLT-4 T-cell 
leukaemic cell lines, in CD28-stimulated Jurkat 
cells, and in 16 of 42 cases of primary T-cell 
lymphoma (but not normal peripheral T 
lymphocytes nor in any subset of thymus-derived 
developing T cells). It is also present in patients 
with hematologic malignancies, including AML, 
CML, MDS, MPN and Multiple Myeloma, and in 
various solid tumours (see below) 
EphA3 expression has been shown to be most 
abundant during vertebrate development, where it is 
highly regulated both temporally and spatially. 
Prominent EphA3 expression occurs in the neural 
system, including the retinal ganglion cells of the 
embryonic retina in a graded distribution from 
anterior/nasal (lowest) to posterior/temporal 
(highest); the cerebrum, thalamus, striatum, 
olfactory bulb, anterior commissure, and corpus 
callosum of the forebrain; and the medial motor 
column ventral motor neurons of the spinal cord; 
and extraneurally by mesodermally-derived tissues 
including the paraxial musculature, tongue 
musculature, submucosa of the soft palate, capsule 
of the submandibular gland, cortical rim of bone, 
thymic septae, media of the pharynx, trachea, great 
vessels, small intestine and portal vein, cardiac 
valves, and the renal medulla. In adult tissues 
EphA3 expression is more restricted and detected at 
significantly lower levels than during early 
development. However it is expressed on 
mesenchymal stromal progenitor cells (MSCs) 
during neovascularisation of the regenerating 
endometrium, with its expression regulated by 
hypoxia. Similarly EphA3 is expressed on MSCs 
recruited from the bone-marrow and contributing to 
the vasculature and supporting stromal tissue of 
various solid cancers . It is also over-expressed on 
progenitor cells in gliomas. In these instances 
EphA3 in tumours is largely inactive, and activation 
with an agonistic antibody inhibits tumour growth. 
Loss of EphA3 expression is also reported in 
cancer. EPHA3 gene copy number and/or 
expression levels were decreased in lung cancers 
(157 of 371 primary lung adenocarcinomas), and 
also in esophageal squamous cell carcinoma 
(ESCC). Silencing of EPHA3 expression by DNA 
hypermethylation occurs in leukaemia , and in 
colorectal tumours carrying a BRAF mutation 
(V600E). Somatic mutations identified in the 3' 
untranslated region of EPHA3 may also disrupt 
miRNA target sites, thereby altering its expression . 
Localisation 
Isoform 1: Cell membrane; single-pass type I 
membrane protein. 
Isoform 2: Secreted. 
Function 
Eph receptors modulate cell shape and movement 
through reorganisation of the cytoskeleton and 
changes in cell-cell and cell-substrate adhesion, and 
are involved in many cellular migration, sorting 
(tissue patterning) and guidance events, most often 
during development, and in particular involving the 
nervous system.  
There is evidence too that Eph receptor signalling 
influences cell proliferation and cell-fate 
determination and growing recognition that Eph 
receptors function in adult tissue homeostasis. 
EphA3 is thought to play a role in retinotectal 
mapping, the tightly patterned projection of retinal 
ganglion cell axons from the retina to the optic 
tectum (or superior colliculus in mammals). In 
chicks, posterior retinal ganglion axons expressing 
highest levels of EphA3 project to the anterior 
tectum where the graded expression of ephrin-A2 
and ephrin-A5 is lowest and are excluded from 
projecting more posteriorly where ephrin-A2/A5 
expression is highest. More direct evidence of non-
redundant function for EphA3 has come from 
phenotypic analysis of EphA3 knockout mice. 
Approximately 70-75% of EphA3 null mice die 
within 48 hours of birth with post-mortem evidence 
of pulmonary oedema secondary to cardiac failure. 
These mice exhibit hypoplastic atrioventricular 
endocardial cushions and subsequent 
atrioventricular valve and atrial membranous septal 
defects, with endocardial cushion explants from 
these mice giving rise to fewer migrating cells 
arising from epithelial to mesenchymal 
transformation.  
Expression of EphA3 in the spinal cord appears to 
be redundant as axial muscle targeting by medial 
motor column motor axons and the organisation of 
the motor neuron columns is not altered. EphA4 is 
the only other EphA receptor also expressed by 
developing spinal cord motor neurons and in mice 
lacking EphA3 and EphA4 these receptors together 
repel axial motor axons from neighbouring ephrin-
A-expressing sensory axons, inhibiting 
intermingling of motor and sensory axons and 
preventing mis-projection of motor axons into the 
dorsal root ganglia. In contrast to the chick, EphA3 
is not expressed by mouse retinal ganglion cells.  











Instead the closely related receptors EphA5 and 
EphA6 (see homology below) are expressed in a 
low nasal to high temporal gradient. However, if 
EphA3 is ectopically expressed in retinal ganglion 
cells in mice these axons project to more rostral 
positions in the superior colliculus. 
A function for soluble EphA3 has not been reported 
although potentially this isoform might play a role 
in promoting cell adhesion (see above) or act as a 
tumour suppressor protein (see below). 
Homology 
Phylogenetic tree for the Eph receptors. Amino acid 
sequences used for this compilation were EphA1 
(NP_005223), EphA2 (NM_004431), EphA3 
(NP_005224), EphA4 (NP_004429), EphA5 
(NM_004439), EphA6 (ENSP00000374323), 
EphA7 (NP_004431), EphA8 (NP_065387), 
EphA10 (NP_001092909), EphB1 (NP_004432), 
EphB2 (NP_004433), EphB3 (NP_004434), EphB4 
(NP_004435) and EphB6 (NP_004436). 
Mutations 
Germinal 
To date no germinal mutations in EPHA3 have  
 
been associated with disease. 
Somatic 
Somatic mutations in EPHA3 have been frequently 
detected, including in lung adenocarcinoma 
(T166N, G187R, S229Y, W250R, M269I, N379K, 
T393K, A435S, D446Y, S449F, G518L, T660K, 
D678E, R728L, K761N, G766E, T933M), 
colorectal carcinoma (T37K, N85S, I621L, S792P, 
D806N), glioblastoma multiforme (K500N, A971P) 
metastatic melanoma (G228R) and pancreatic 
cancer (K207N).  
Two mutations are reported in haematological 
malignancies: R897M in mantle cell lymphoma and 
a truncating E461X mutation in a t(4;14) myeloma 
(with FGFR3/ WHSC1 (MMSET) translocation). 
According to the COSMIC catalogue of somatic 
mutations in cancer (http://cancer.sanger.ac.uk) 
there are over 300 reported mutations, which are 
distributed over all regions encoding functional 
domains, most prominently in the extracellular 
domains involved in ligand-receptor and receptor-
receptor interactions, and in the intracellular kinase 
domain.  
Several mutations have been confirmed to inhibit 
receptor activity and cell surface expression. 
 
Figure 6: Sites of somatic mutations in EphA3 identified in lung adenocarcinoma colorectal carcinoma, glioblastoma multiforme, 
metastatic melanoma and pancreatic cancers (PDAC and AVC). 










EPHA3 was among the genes whose expression 
was upregulated during androgen-independent 
progression in an LNCaP in vitro cell model of 
prostate cancer.  
Subsequently, EphA3 was found to correlate with 
proliferation and survival of prostate cancer cells 
and tumour growth in mice, and was upregulated in 
stromal cells at sites of bone metastasis. 
Melanoma 
A melanoma patient with an especially favourable 
evolution of disease, associated with a very strong 
and sustained anti-tumour cytotoxic T lymphocyte 
response, was found to have a lytic CD4 clone that 
recognised an EphA3 antigen presented by the 
HLA class II molecule HLA- DRB1*1101. 94% 
(75 of 80) of melanomas examined expressed 
EphA3 in contrast to normal melanocytes which do 
not express detectable EphA3. 
Lung cancer, Sarcoma, and Renal 
cell carcinoma 
44% (11 of 25) of small cell lung cancer, 24% (10 
of 41) of non-small cell lung cancer, 58% (17 of 
29) of sarcomas, and 31% (12 of 38) of renal cell 
carcinomas expressed EphA3 at levels significantly 
higher than the corresponding normal tissues. 
Liver, gastric, and colorectal cancer 
High EphA3 expression associated with high 
invasive capacity and poor overall survival in 
hepatocellular carcinoma, and with angiogenesis 
and poor prognosis in gastric cancer.  
In colorectal cancer, high expression correlates with 
stem cell marker expression, and with tumour size 
and grade, infiltration and metastasis. 
Hematological tumours 
Increased expression in 50% of patients with 
myelodysplastic syndrome, acute myeloid 
leukaemia or chronic myeloid leukaemia (CML), 
most prominent on a leukaemia stem cell 
immunophenotype.  
Overexpression in a high proportion of the other 
chronic myeloproliferative diseases was also 
observed. 
Glioma 
40% glioma specimens over-expressed EphA3, 
particularly in mesenchymal subtype.  
Expression on cancer initiating/stem cell type. 
Radio-labelled antibody targeting in mouse model 
inhibited growth. 
Other solid tumours: bladder, brain, 
breast, colon, kidney, liver, lung, 
melanoma, prostate 
Over-expressed in high proportion of tumour 
vasculature and stromal tissues, even when not in 
the tumour bulk.  
Expressed on mesenchymal stromal cells recruited 
from bone marrow. Targeting with activating 
antibody inhibited tumour growth in mouse models. 
Breakpoints 
No reported breakpoints identified to date nor 
recognised fusion proteins involving EphA3. 
To be noted 
Soluble forms of EphA3 appear to inhibit tumour 
angiogenesis and tumour progression suggesting 
that specific inhibition by soluble EphA3 may be 
therapeutically useful. 
The IIIA4 monoclonal antibody originally raised 
against LK63 human acute pre-B leukemia cells 
and used to affinity isolate EphA3 binds the native 
EphA3 globular ephrin-binding domain with sub-
nanomolar affinity (KD ~5x10-10 mol/L).  
Like ephrin-A5, pre-clustered IIIA4 effectively 
triggers EphA3 activation, contraction of the 
cytoskeleton, and cell rounding.  
Moreover, radio-metal conjugates of ephrin-A5 and 
IIIA4 retain their EphA3-binding affinity, and in 
mouse xenografts localise to, and are internalised 
rapidly into EphA3-positive, human tumours. 
Treatment of tumour xenografts with IIIA4 alone, 
or with radio-labelled IIIA4, can inhibit tumour 
growth. A humanised version of IIIA4 has been 
developed, with enhanced affinity and antibody-
dependent cell-mediated cytotoxicity (ADCC) 
activity against EphA3-expressing leukemic cells, 
and is being investigated in Phase I/II clinical trials. 
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